The Team

JOE DOUGHERTY, PH.D. (MANAGING DIRECTOR)

Joe Dougherty brings over 25 years of experience in science, biotechnology companies, and finance to Seaview Securities.

Prior to co-founding Seaview Securities, Dr. Dougherty was a senior biotechnology research analyst covering a full range of large and small cap product and genomics companies at Lehman Brothers. Between 1997 and 2002, Dr. Dougherty advised on and helped market in excess of 45 biotechnology transactions valued at over $6 billion while at Lehman Brothers from 2000 to 2002 and Warburg Dillon Read (now UBS) from 1997 to 2000.

Before entering the securities industry as a Wall Street analyst, Dr. Dougherty was a research scientist at Gilead Sciences (1992-1997) where he co-invented the PMPA prodrug now marketed as Viread®.

At Genetics Institute (1983-1987), Dr. Dougherty worked on the synthesis of modified nucleic acids, methodologies for DNA-based diagnostics, and nucleic acid-targeted drugs.

Dr. Dougherty received his Ph.D. in Bioorganic Chemistry from Columbia University (Laboratory of Ronald Breslow) and an A.B. in Chemistry from Harvard University (Laboratory of William von Eggers Doering). He has authored numerous scientific articles and obtained several patents.

Dr. Dougherty was a director of AnorMED, Inc. until November 2006, and chaired its Strategic Initiatives Committee during the hostile takeover process that led to its acquisition by Genzyme.